Nitrile-Based Heme Inhibitors for Selective Metalloprotein Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in selectively targeting heme proteins due to promiscuity issues with hemoglobin and myoglobin, making it difficult to develop effective metal binding inhibitors for heme-based metalloproteins, which are crucial for treating diseases and infections.
Innovation Solution
A novel heme-tethering approach using nitrile-based pharmacophores that bind specifically to ferric heme iron, exploiting differences in gas tunnel architecture to block competing substrates and enhance selectivity, as demonstrated by the compound HT-N6, which shows high affinity for therapeutically relevant heme proteins like DosS while avoiding ubiquitous heme proteins in mammals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metal binding inhibitors are developed to target heme proteins, then therapeutic potential is improved, but selectivity deteriorates due to promiscuity with hemoglobin and myoglobin
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features that interact with local characteristics of the gas tunnel in target heme proteins. The inhibitors contain aromatic rings and heteroatoms that form specific interactions (pi-stacking, hydrogen bonding) with residues lining the gas tunnel, providing selectivity for enzymes like cytochrome P450 while avoiding promiscuous binding to hemoglobin and myoglobin.
Solution Approach 2:
The patent employs parameter changes by modifying molecular properties such as aromaticity, heteroatom composition, and spatial configuration of the inhibitor molecules. These parameter changes enable the inhibitors to achieve optimal binding affinity and selectivity for ferric heme iron in target enzymes while discriminating against other heme proteins based on subtle differences in their gas tunnel architectures.
2Reliability
If metal binding inhibitors are designed to target active site metal, then inhibition efficacy is improved, but selectivity deteriorates due to promiscuity of heme proteins at millimolar concentrations
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a metal-binding moiety (for ferric heme iron coordination) and a gas tunnel-targeting moiety (for selective recognition). This segmentation allows the inhibitor to first bind to the metal center for efficacy, then use the gas tunnel moiety to achieve selectivity by exploiting architectural differences in the gas tunnel of target versus off-target heme proteins.
Solution Approach 2:
The gas tunnel acts as an intermediary structure that mediates between the metal-binding site and the external environment. The patent exploits this intermediary by designing inhibitors that use the gas tunnel architecture as a selective filter - the tunnel's size, shape, and residue composition create a steric and chemical barrier that allows binding to target enzymes while preventing promiscuous binding to hemoglobin and myoglobin.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for selective inhibition of therapeutically relevant heme enzymes, overcoming promiscuity issues and achieving significant binding affinity, particularly for ferric forms of heme proteins like DosS, with minimal interaction with mammalian heme proteins, thus offering a promising strategy for drug development.
Implementation Method 1
nitrile-based pharmacophores that bind specifically to ferric heme iron
Implementation Method 2
exploiting differences in gas tunnel architecture to block competing substrates
Data Source
AI summary
Disclosed herein are methods to inhibit a metalloprotein and methods to treat diseases and crop infections with a compound of formula I:X-L-Y Ior a salt thereof. Also disclosed are novel compounds of formula I or a salt thereof and compositions comprising a compound of formula I.